These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 15550585)

  • 21. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
    Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
    J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
    Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
    Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
    Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
    J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.
    Canellos GP; Anderson JR; Propert KJ; Nissen N; Cooper MR; Henderson ES; Green MR; Gottlieb A; Peterson BA
    N Engl J Med; 1992 Nov; 327(21):1478-84. PubMed ID: 1383821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?
    Laskar S; Gupta T; Vimal S; Muckaden MA; Saikia TK; Pai SK; Naresh KN; Dinshaw KA
    J Clin Oncol; 2004 Jan; 22(1):62-8. PubMed ID: 14657226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease.
    Ng AK; Li S; Neuberg D; Silver B; Stevenson MA; Fisher DC; Mauch PM
    Ann Oncol; 2004 Feb; 15(2):270-5. PubMed ID: 14760121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
    J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
    Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
    Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial.
    Hutchinson RJ; Fryer CJ; Davis PC; Nachman J; Krailo MD; O'Brien RT; Collins RD; Whalen T; Reardon D; Trigg ME; Gilchrist GS
    J Clin Oncol; 1998 Mar; 16(3):897-906. PubMed ID: 9508171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma.
    Vassilakopoulos TP; Angelopoulou MK; Siakantaris MP; Kontopidou FN; Dimopoulou MN; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Karkantaris C; Anargyrou K; Boutsis DE; Variamis E; Michalopoulos T; Boussiotis VA; Panayiotidis P; Papavassiliou C; Pangalis GA
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):765-81. PubMed ID: 15183480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.
    Takenaka T; Mikuni C; Miura A; Sasaki T; Suzuki H; Hotta T; Hirano M; Fukuhara S; Sugiyama H; Nasu K; Dohi H; Kozuru M; Tomonaga M; Tajima K; Niimi M; Fukuda H; Mukai K; Shimoyama M
    Jpn J Clin Oncol; 2000 Mar; 30(3):146-52. PubMed ID: 10798542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study.
    Pavone V; Ricardi U; Luminari S; Gobbi P; Federico M; Baldini L; Iannitto E; Ucci G; Marcheselli L; Orsucci L; Angelucci E; Liberati M; Gavarotti P; Levis A;
    Ann Oncol; 2008 Apr; 19(4):763-8. PubMed ID: 18180244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy.
    Brusamolino E; Orlandi E; Morra E; Castelli G; Pagnucco G; Livraghi A; Astori C; Santagostino A; Lazzarino M; Bernasconi C
    Ann Oncol; 1994; 5 Suppl 2():53-7. PubMed ID: 7515648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advanced stage and unfavorable Hodgkin's disease in the Chinese-a 20-year experience.
    Chim CS; Kwong YL; Lie AK; Lee CK; Ho FC; Liang R
    Am J Hematol; 1999 Jul; 61(3):159-63. PubMed ID: 10398307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
    Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial.
    Sieber M; Tesch H; Pfistner B; Rueffer U; Paulus U; Munker R; Hermann R; Doelken G; Koch P; Oertel J; Roller S; Worst P; Bischof H; Glunz A; Greil R; von Kalle K; Schalk KP; Hasenclever D; Brosteanu O; Duehmke E; Georgii A; Engert A; Loeffler M; Diehl V; Mueller RP; Willich N; Fischer R; Hansmann ML; Stein H; Schober T; Koch B;
    Ann Oncol; 2004 Feb; 15(2):276-82. PubMed ID: 14760122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: results of a prospective clinical trial with 70 stage IIIB-IV patients.
    Fermé C; Lepage E; Brice P; D'Agay MF; Fermand JP; Castaigne S; Frija J; Miot C; Marty M; Gisselbrecht C
    Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):397-405. PubMed ID: 7685749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.
    Schlembach PJ; Wilder RB; Jones D; Ha CS; Fayad LE; Younes A; Hagemeister F; Hess M; Cabanillas F; Cox JD
    Cancer J; 2002; 8(5):377-83. PubMed ID: 12416895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternating versus hybrid MOPP-ABVD in Hodgkin's disease: the Milan experience.
    Viviani S; Bonadonna G; Santoro A; Zanini M; Zucali R; Negretti E; Valagussa P
    Ann Oncol; 1991 Feb; 2 Suppl 2():55-62. PubMed ID: 1710921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease.
    Gustavsson A
    Acta Oncol; 1997; 36(5):483-8. PubMed ID: 9292744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.